Jim O'Neill, a Silicon Valley investment manager, would be an unusual choice to head US FDA, not just because he isn’t a physician, but because he’s favored substantially reducing FDA's role in assessing product effectiveness. While some experts are highly skeptical about O'Neill, who worked at HHS in the Bush administration, others suggest he could champion much-needed change at the agency.
A purported candidate to run FDA under the Trump administration would bring what some consider troubling views and experience to the commissioner post, but regulatory affairs stakeholders say Silicon Valley investor Jim O'Neill could be an interesting pick.
President-elect Donald Trump is reportedly considering replacing FDA Commissioner Robert Califf with O'Neill, an associate of the controversial Silicon Valley...
Neither Kamala Harris nor Donald Trump mentioned drug pricing reforms in their presidential convention speeches.
The agency is clearly on the radar of former President Trump and his new coterie of tech moguls.
With the 4 July UK general election less than two weeks away, the Pink Sheet looks at the manifestos published by the major political parties and finds pledges to drive innovation, boost clinical trial activity and speed up regulatory procedures.
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.
Congressional Budget Office responses to questions from US lawmakers on pharmacy benefit managers could add to the momentum for PBM reforms to go further than the current leading proposals.
Letter to US FDA by a bipartisan group of House members cites clinical trials sponsored by Eli Lilly and Pfizer as examples of a widespread industry practice. But any legislation to curtail such practices is not expected to be part of the BIOSECURE Act.
The agency is clearly on the radar of former President Trump and his new coterie of tech moguls.
